Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO · Healthcare

₹2,896.40

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bearish 62% confidence

Momentum collapse (1-month -7.21%), volume drought (21% of average), and complete absence of earnings visibility outweigh bullish EMA…

Strongest bull point

Bullish EMA stack (20>50>200) with price 7.87% above 200-day moving average confirms intact uptrend structure, and 11.33 percentage point outperformance versus NIFTY over 12 months demonstrates relative strength in a weak market.

Strongest bear point

Recent momentum has collapsed (1-month -7.21% versus 3-month +19.59%), volume has dried to 21% of average signaling weak conviction, and no Q2 earnings visibility exists to validate the 12-month outperformance or justify current valuation.

Technical Forecast · next 10 trading days

Expected

₹2,514.09 -13.2%

Range

₹2,511.98 – ₹2,528.19

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on GLAXO, misses included

Bearish 28 Sep 2026 → now Scores 28 Oct 2026

₹2,896.40 → ₹2,896.40 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare